Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Large-scale molecular dynamics simulation: Effect of polarization on thrombin-ligand binding energy.

Duan LL, Feng GQ, Zhang QG.

Sci Rep. 2016 Aug 10;6:31488. doi: 10.1038/srep31488.

2.

The Fragment 1 Region of Prothrombin Facilitates the Favored Binding of Fragment 12 to Zymogen and Enforces Zymogen-like Character in the Proteinase.

Bradford HN, Krishnaswamy S.

J Biol Chem. 2016 May 20;291(21):11114-23. doi: 10.1074/jbc.M116.723072.

PMID:
27013660
3.

Modulation of Intrinsically Disordered Protein Function by Post-translational Modifications.

Bah A, Forman-Kay JD.

J Biol Chem. 2016 Mar 25;291(13):6696-705. doi: 10.1074/jbc.R115.695056. Review.

PMID:
26851279
4.

Inhibition of thrombin generation in human plasma by phospholipid transfer protein.

Deguchi H, Wolfbauer G, Cheung MC, Banerjee Y, Elias DJ, Fernández JA, Albers JJ, Griffin JH.

Thromb J. 2015 Jul 16;13:24. doi: 10.1186/s12959-015-0054-0.

7.

Amino acid region 1000-1008 of factor V is a dynamic regulator for the emergence of procoagulant activity.

Wiencek JR, Na M, Hirbawi J, Kalafatis M.

J Biol Chem. 2013 Dec 27;288(52):37026-38. doi: 10.1074/jbc.M113.462374.

8.

Biochemomechanics of intraluminal thrombus in abdominal aortic aneurysms.

Wilson JS, Virag L, Di Achille P, Karsaj I, Humphrey JD.

J Biomech Eng. 2013 Feb;135(2):021011. doi: 10.1115/1.4023437. Review.

9.

Crosstalk between Platelets and the Immune System: Old Systems with New Discoveries.

Li C, Li J, Li Y, Lang S, Yougbare I, Zhu G, Chen P, Ni H.

Adv Hematol. 2012;2012:384685.

10.

The prothrombotic phenotypes in familial protein C deficiency are differentiated by computational modeling of thrombin generation.

Brummel-Ziedins KE, Orfeo T, Callas PW, Gissel M, Mann KG, Bovill EG.

PLoS One. 2012;7(9):e44378. doi: 10.1371/journal.pone.0044378.

11.

Meizothrombin is an unexpectedly zymogen-like variant of thrombin.

Bradford HN, Krishnaswamy S.

J Biol Chem. 2012 Aug 31;287(36):30414-25. doi: 10.1074/jbc.M112.394809.

12.

Preventing platelet thrombosis with a PAR1 pepducin.

Abdel-Latif A, Smyth SS.

Circulation. 2012 Jul 3;126(1):13-5. doi: 10.1161/CIRCULATIONAHA.112.122317. No abstract available.

13.

Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.

Fintel DJ.

Vasc Health Risk Manag. 2012;8:77-89. doi: 10.2147/VHRM.S26030. Review.

14.

Rigidification of the autolysis loop enhances Na(+) binding to thrombin.

Pozzi N, Chen R, Chen Z, Bah A, Di Cera E.

Biophys Chem. 2011 Nov;159(1):6-13. doi: 10.1016/j.bpc.2011.04.003.

15.

Inhibitors of the initiation of coagulation.

Ott I.

Br J Clin Pharmacol. 2011 Oct;72(4):547-52. doi: 10.1111/j.1365-2125.2011.03960.x. Review.

16.

Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease.

Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, Akter T, van Ryn J, Silver RM.

Arthritis Rheum. 2011 May;63(5):1416-25. doi: 10.1002/art.30255.

17.

Cellular regulation of blood coagulation: a model for venous stasis.

Campbell JE, Brummel-Ziedins KE, Butenas S, Mann KG.

Blood. 2010 Dec 23;116(26):6082-91. doi: 10.1182/blood-2010-01-266395.

18.

Evidence of the E*-E equilibrium from rapid kinetics of Na+ binding to activated protein C and factor Xa.

Vogt AD, Bah A, Di Cera E.

J Phys Chem B. 2010 Dec 16;114(49):16125-30. doi: 10.1021/jp105502c.

19.

Ligand binding shuttles thrombin along a continuum of zymogen- and proteinase-like states.

Kamath P, Huntington JA, Krishnaswamy S.

J Biol Chem. 2010 Sep 10;285(37):28651-8. doi: 10.1074/jbc.M110.154914.

20.

Combinatorial enzyme design probes allostery and cooperativity in the trypsin fold.

Page MJ, Di Cera E.

J Mol Biol. 2010 Jun 4;399(2):306-19. doi: 10.1016/j.jmb.2010.04.024.

Items per page

Supplemental Content

Support Center